Cohance Lifesciences Ltd
NSE: COHANCE BSE: 543064
₹311.95
(3.48%)
Wed, 08 Apr 2026, 07:02 am
Market Cap115.5B
PE Ratio54.25
Dividend0
Health Technology
Pharmaceuticals: Major
24.5KCohance Lifesciences Analysis
dividend
- Unable to evaluate Suven Pharmaceuticals's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
- Unable to evaluate Suven Pharmaceuticals's dividend against the top 25% market benchmark as the company has not reported any payouts.
health
- Suven Pharmaceuticals has no long term commitments.
- Low level of unsold assets.
- Suven Pharmaceuticals's short term (1 year) commitments are greater than its holdings of cash and other short term assets.
- Operating cash flow is negative therefore debt is not well covered.
- Suven Pharmaceuticals has negative shareholder equity (liabilities exceed assets) therefore debt is not covered by short term assets.
- Irrelevant to check if Suven Pharmaceuticals's debt level has increased considering it has negative shareholder equity.
- Suven Pharmaceuticals has negative shareholder equity (liabilities exceed assets), this is a more serious situation compared with a high debt level.
misc
- Suven Pharmaceuticals is not covered by any analysts.
- Suven Pharmaceuticals's last earnings update was 389 days ago.
- Suven Pharmaceuticals has significant price volatility in the past 3 months.
past
- Unable to compare Suven Pharmaceuticals's 1-year earnings growth to the 5-year average as it is not currently profitable.
- Suven Pharmaceuticals does not make a profit and there is insufficient past data to establish if their 5 year on year earnings growth rate was positive.
- It is difficult to establish if Suven Pharmaceuticals has efficiently used its assets last year compared to the IN Pharmaceuticals industry average (Return on Assets) as it is loss-making.
- It is difficult to establish if Suven Pharmaceuticals improved its use of capital last year versus 3 years ago (Return on Capital Employed) due to its liabilities exceeding its assets.
- It is difficult to establish if Suven Pharmaceuticals has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) due to its liabilities exceeding its assets.
- Unable to compare Suven Pharmaceuticals's 1-year growth to the IN Pharmaceuticals industry average as it is not currently profitable.
value
- Suven Pharmaceuticals has negative assets, we can't compare the value of its assets to the IN Pharmaceuticals industry average.
- Suven Pharmaceuticals is loss making, we can't compare its value to the IN Pharmaceuticals industry average.
- Suven Pharmaceuticals is loss making, we can't compare the value of its earnings to the India market.
- NSEI:SUVENPHAR is flat (-0.6%) underperforming the Pharmaceuticals industry which returned 6.8% over the past month.
- NSEI:SUVENPHAR is flat (-0.6%) underperforming the market in India which returned 8% over the past month.
Open Your Free Demat Account Now!
Facebook
Twitter
Instagram
LinkedIn
Youtube
Calculators
Popular Calculators
Group Stocks
Pocketful Fintech Capital Private Limited (CIN U65999DL2021PTC390548) | The SEBI Registration No. allotted to us is INZ000313732. NSE Member Code: 90326 | BSE Member Code: 6808 | MCX Member Code: 57120 DP | CDSL: 12099800